Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients aged ≥18 years (≥20 years in Taiwan) at the time of informed consent~2. Patients who meet the 1987 revised ACR criteria or 2010 ACR/EULAR criteria~3. Patients who have RA within 2 years from initial diagnosis to informed consent~4. Patients who were previously untreated with MTX, JAK inhibitor, or bDMARDs~5. Patients who have disease activity of SDAI \>11 at screening~6. Patients who are no need for concomitant use of DMARDs other than hydroxychloroquine (only in South Korea and Taiwan) and study drugs during the study as judged by principal investigator/sub-investigator at screening~7. Patients who are no need for concomitant use of corticoid steroid equivalent to \>10 mg/day prednisolone during the study as judged by principal investigator/sub-investigator at screening.~8. Female of child-bearing potential who can use appropriate contraceptive during the study, female in whom time from menopause to informed consent is ≥1 year, or female of no child-bearing potential through sterilization (bilateral tubal ligation, bilateral ovariectomy or hysterectomy, etc.)~9. Virile male who can use appropriate contraceptive during the study~10. Patients who can adequately understand this study procedures, and voluntarily consent in writing to take part in this study (consent of a legally-acceptable representative is also required for patients aged \<20 years in Japan and aged \<19 years in South Korea)~Exclusion Criteria:~1. Patients who currently have a malignant tumor, except for non-melanoma forms of skin cancer limited within epidermis, and uterine cervix cancer limited within epidermis~2. Patients who have serious infections such as sepsis~3. Patients who have active tuberculosis~4. Patients who have a history or current complication of demyelinating disease such as multiple sclerosis~5. Patients who have congestive heart failure~6. Pregnant female, or female who intend to conceive during the study period~7. Patients who have bone marrow depression and whom investigator considered ineligible~8. Patients who have chronic liver disease and whom investigator considered ineligible, and who is positive for HBs antigen~9. Patients who have nephropathy and whom investigator considered ineligible~10. Lactating female~11. Patients who have pleural effusion or ascites~12. Patients with a known hypersensitivity to MTX or ADA~13. Patients otherwise whom principal investigator/sub-investigator considered medically ineligible to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MTX-Monotherapy Group (Type: EXPERIMENTAL): Participants will receive Methotrexate (MTX) at a starting dose of 6 to 8 mg/week, which will be promptly escalated to the maximum tolerated dose (MTD) of ≤25 mg/week up to Week 12, and maintained until Week 24. If the dosage of MTX is maintained ≥ 10 mg/week and simple disease activity index (SDAI) remission is achieved at Week 24, the MTX therapy will continue until Week 48.
- ADA/MTX-Maximum Tolerated Dose Group (Type: EXPERIMENTAL): Participants will receive Methotrexate (MTX) at a starting dose of 6 to 8 mg/week, which will be promptly escalated to the MTD of ≤25 mg/week up to Week 12, and maintained until Week 24. If the dosage of MTX is maintained ≥ 10 mg/week and SDAI remission is not achieved at Week 24, Adalimumab (ADA) 40 mg will be administered subcutaneously every other week in addition to the MTX therapy until Week 48.
- ADA/MTX-Reduced Dose Group (Type: EXPERIMENTAL): Participants will receive Methotrexate (MTX) at a starting dose of 6 to 8 mg/week, which will be promptly escalated to the MTD of ≤25 mg/week up to Week 12, and maintained until Week 24. If the dosage of MTX is maintained ≥ 10 mg/week and SDAI remission is not achieved at Week 24, Adalimumab (ADA) 40 mg will be administered subcutaneously every other week in addition to low-dose MTX (6 to 8 mg/week) treatment until Week 48.

Based on this trial design, predict the completion outcome and termination type (if applicable).